TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality. 

angulación aórtica post TAVR

The association between severe aortic stenosis (SAS) and hypertrophic cardiomyopathy (HCM) is increasingly frequent.

Currently, the available information on this scenario is limited and comes mainly from small registries or the analysis conducted by Mhanna et al., who compared transcatheter aortic valve replacement (TAVR) with surgery in this patient group. The results showed that TAVR was associated with lower in-hospital mortality, fewer complications, reduced need for vasoactive drugs, lower incidence of cardiogenic shock, and a shorter hospital stay.

Researchers conducted a meta-analysis including 1095 patients with SAS and HCM. 

Patients with HCM experienced the following:

  • Five times higher mortality rates (odds ratio [OR] 5.79; 95% confidence interval [CI]: 3.38-9.91, p <0.0001; I² = 85%).
  • Four times higher incidence of cardiogenic shock (OR 4.55; 95% CI: 3.40-6.08, p <0.0001; I² = 48%).
  • Higher incidence of vascular complications (OR 2.10; 95% CI: 1.27-3.47, p = 0.004; I² = 14%).
  • Increased renal failure (OR 1.80; 95% CI: 1.36-2.40, p <0.0001; I² = 64%).
  • Greater risk of aortic dissection (OR 4.95; 95% CI: 3.17-7.74, p <0.0001; I² = 0%).

Read also: Mechanical Circulatory Support in Complex Anatomies and Severe Deterioration of Left Ventricular Function.

There were no significant differences in the incidence of atrioventricular (A-V) block, need for permanent pacemaker, or bleeding events.

Conclusion

In patients with severe aortic stenosis and associated hypertrophic cardiomyopathy, TAVR was linked to a higher incidence of mortality, cardiogenic shock, aortic dissection, vascular complications, renal failure, and an increased need for mechanical ventilation compared to those without hypertrophic cardiomyopathy.

Original Title: Transcatheter Aortic Valve Replacement in Hypertrophic Cardiomyopathy: A Systematic Review and Meta‐ Analysis

Reference: Ashraf Ahmed, et al. Catheterization and Cardiovascular Interventions, 2025; 105:754–760 https://doi.org/10.1002/ccd.31367


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...